Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian pharma: Where do you go... - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • May 27, 2004

    Indian pharma: Where do you go...

    Indian pharma companies have shown very good growth numbers in last few years. While big guns have made their presence felt in the international business, some smaller companies too have made their space in the Indian pharmaceutical industry. If the current growth pace of pharma companies continues for some more time, we will have a dozen Rs 10 bn companies in about two years' time.

    The table below reveals the growth patterns of the top 5 Indian pharma companies by sales over the last three years. Ranbaxy, Cipla, Dr. Reddy's, Nicholas Pharma and Aurobindo Pharma are the top Indian companies in the industry. Barring Nicholas Piramal, the rest have done considerably well largely owing to their exploits on the global front. Several other companies, like Sun Pharma, Wockhardt, Lupin Labs and Cadila are also taking this route.

    Consolidated Revenues...
    (Rs m) FY02 FY03 FY04 CAGR
    Ranbaxy 27,580 39,156 44,609 27.2%
    Cipla 12,745 15,728 20,600 27.1%
    Dr Reddy's 16,093 17,136 19,720 10.7%
    Nicholas 8,662 9,642 12,961 22.3%
    Aurbindo 9,737 11,139 13,221 16.5%

    The major growth for these companies has been their international operations. Companies like Cipla who were laggards in this area, have now taken a lead in bulk drug exports and about 56% of the incremental growth for the company in FY04 has come from international business. But companies like Ranbaxy and Dr Reddy's, which started as bulk drug suppliers, have now moved up the value chain and entered the lucrative US and European generics markets. Currently, 24% of Ranbaxy's revenues comes from international business, which has clocked a CAGR of 38% in last five years. But this exemplary performance of the Indian companies has come in the backdrop on changing international trade conditions where all the WTO member companies will follow product patent regime. Fearing that they will be wiped out in the fierce competition with international majors, Indian companies started looking out for markets globally.

    This growth in the international business has come on the back of cost competitiveness and expertise in chemical synthesis. Also, globally pharma companies are focusing on cost control measures and India is fast becoming a preferred destination to outsource their lesser value-add activities. Infact, Indian companies are the largest drug master file (DMF) applicants with the USFDA constituting 22% of the total DMF applications currently.

    Going forward, these companies are going to show healthy growth rates given the international compulsions and opportunities. The above chart shows that the bulk drugs lies at the bottom of the value chain. An important thing to note is that the basic nature of bulk drugs is similar to that of commodities. Intensifying competition in this field will put pressure on the margins of the companies in the years to come.

    While this threat is still some time away, to avoid this and for sustainable long term survival, the way forward is clearly to invest in R&D activities and move above the value chain. Not all companies need to look at pure research (search for new molecules). Some are already proving to be a viable global supplier of bulk drugs, some are setting themselves up as value for money service providers for clinical trials. But activities will only suffice till the next decade. Post that, in a patent regime, pure R&D led companies will call the shots. Therefore, for the good of domestic pharma industry, Indian companies must invest their cash earned from the bulk drugs and plain generic activities towards research in order to move up the value chain.



    Equitymaster requests your view! Post a comment on "Indian pharma: Where do you go...". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 11:36 AM